Opin vísindi

DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients

Show simple item record

dc.contributor Háskóli Íslands
dc.contributor University of Iceland
dc.contributor.author Amirfallah, Arsalan
dc.contributor.author Kocal, Gizem
dc.contributor.author Unal, Olcun
dc.contributor.author Ellidokuz, Hulya
dc.contributor.author Oztop, Ilhan
dc.contributor.author Basbinar, Yasemin
dc.date.accessioned 2019-08-12T15:56:53Z
dc.date.available 2019-08-12T15:56:53Z
dc.date.issued 2018-12-13
dc.identifier.citation Amirfallah A, Calibasi Kocal G, Unal OU, Ellidokuz H, Oztop I, Basbinar Y. DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients. Journal of Personalized Medicine. 2018; 8(4):45. doi:10.3390/jpm8040045
dc.identifier.issn 2075-4426
dc.identifier.uri https://hdl.handle.net/20.500.11815/1210
dc.description Publisher's version (útgefin grein)
dc.description.abstract Fluoropyrimidine-based chemotherapy is extensively used for the treatment of solid cancers, including colorectal cancer. However, fluoropyrimidine-driven toxicities are a major problem in the management of the disease. The grade and type of the toxicities depend on demographic factors, but substantial inter-individual variation in fluoropyrimidine-related toxicity is partly explained by genetic factors. The aim of this study was to investigate the effect of dihydropyrimidine dehydrogenase (DPYD), thymidylate synthase (TYMS), and methylenetetrahydrofolate reductase (MTHFR) polymorphisms in colorectal cancer patients. Eighty-five patients who were administered fluoropyrimidine-based treatment were included in the study. The DPYD, TYMS and MTHFR polymorphisms were scanned by a next generation Sequenom MassARRAY. Fluoropyrimidine toxicities were observed in 92% of all patients. The following polymorphisms were detected: DPYD 85T>C (29.4% heterozygote mutants, 7.1% homozygote mutants), DPYD IVS 14+1G>A (1.2% heterozygote mutants), TYMS 1494del TTAAAG (38.4% heterozygote mutants, 24.7% homozygote mutants), MTHFR 677C>T (43.5% heterozygote mutants, 9.4% homozygote mutants) and MTHFR 1298A>C (8.2% heterozygote mutants, 2.4% homozygote mutants). A statistically significant association was demonstrated between MTHFR 677C>T and fluoropyrimidine-related toxicity (p value = 0.007). Furthermore, MTHFR 1298A>C was associated with hematopoietic toxicity (p value = 0.008). MTHFR polymorphisms may be considered as related factors of fluoropyrimidine toxicity and may be useful as predictive biomarkers for the determination of the colorectal cancer patients who can receive the greatest benefit from fluoropyrimidine-based treatments.
dc.description.sponsorship This work was supported by Dokuz Eylul University Research Foundation [Grant number: 2013.KB.SAG.036].
dc.format.extent 45
dc.language.iso en
dc.publisher MDPI AG
dc.relation.ispartofseries Journal of Personalized Medicine;8(4)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Colorectal cancer
dc.subject DPYD
dc.subject Pharmacogenetics
dc.subject Polymorphisms
dc.subject TYMS and MTHFR gene
dc.subject Krabbamein
dc.subject Lyfjameðferð
dc.subject Lyfjafræði
dc.subject Erfðafræði
dc.title DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients
dc.type info:eu-repo/semantics/article
dcterms.license This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.description.version Peer Reviewed
dc.identifier.journal Journal of Personalized Medicine
dc.identifier.doi 10.3390/jpm8040045
dc.relation.url http://www.mdpi.com/2075-4426/8/4/45/pdf
dc.contributor.department Læknadeild (HÍ)
dc.contributor.department Faculty of Medicine (UI)
dc.contributor.school Heilbrigðisvísindasvið (HÍ)
dc.contributor.school School of Health Sciences (UI)

Files in this item

This item appears in the following Collection(s)

Show simple item record